This month on Nursing Excellence in Cancer Care we discuss living with metastatic ovarian cancer. Available exclusively to members, we encourage you to login and listen today!
Following the 1 March 2026 Pharmaceutical Benefits System (PBS) updated listings for ipilimumab and nivolumab for the treatment of immunotherapy sensitive, advanced or metastatic cancers, eviQ has published its first broad indication tumour-agnostic immunotherapy protocol.
Australia now has clarity it has never had before: 20,950 Australians are living with metastatic breast cancer — more than double what was previously understood. This new national estimate exposes decades of undercounting, underestimated need, and under-resourced care.
This practical session focused on supporting people with treatable, but not curable cancers, and included presentations from experts in the field, a consumer with lived experience, and a facilitated panel discussion.
